Soares Rafael de Athayde, Amaro Kaline, Nasser Ana Isabel, Cury Marcus Vinícius Martins, Nakamura Edson Takamitsu, Pedrosa Keityane de Lima, Sacilotto Roberto
Division of Vascular and Endovascular Surgery, Hospital Do Servidor Público Estadual de São Paulo, Sao Paulo, Brazil.
Vascular. 2025 Aug;33(4):770-778. doi: 10.1177/17085381241264381. Epub 2024 Jul 19.
ObjectiveThe main objective of this paper is to evaluate the outcomes regarding endoleaks, reinterventions, and death related to aneurysm complications in patients submitted to endovascular repair (EVAR) for abdominal aortoiliac aneurysm (AAA) using Endurant II (Medtronic) and Zenith Flex (Cook) endografts.MethodsThis was a prospective, consecutive cohort study of patients with AAA who underwent EVAR with the use of Endurant II stent graft and Zenith Flex endograft.ResultsA total of 156 patients submitted to EVAR were evaluated. The perioperative mortality was 5.1%, 8 patients. The median clinical follow-up period was 760 ± 80 days. There were 28 patients (17.9%) submitted to urgent repair of the aneurysm (symptomatic expansion or rupture) and 128 patients (82.1%) submitted to elective repair. There were 36 cases (23.1%) of later endoleak and most of them are Type II endoleaks (21 patients, 13.4%). There were 12 cases of Type I endoleak. Moreover, regarding limb graft occlusion (LGO), there were 9 patients (5.8%). The overall survival rate in Kaplan-Meier analysis at 720 days was 84.8% in the total cohort. The freedom from reintervention rate in Kaplan-Meier analysis at 720 days was 92.7% in the total cohort. The linear regression analysis for survival rates showed that chronic kidney disease ( = .03; hazard ratio (HR) = 2.82, CI = 1.07-4.44) was the only factor related to poorer survival rates in both univariate and multivariate analyses. The linear regression analysis showed that the presence of endoleaks ( < .001, HR = 6.69, CI = 2.26-8.48) and limb graft occlusion ( < .001, HR = 8.02, CI = 1.60-9.99) were related to reintervention in both univariate and multivariate analyses.ConclusionIn this present study, supra-renal fixation endograft devices were safe and efficient in treating AAA, with satisfactory results and no renal compromise. The linear regression analysis showed that the presence of endoleaks and limb graft occlusion were related to higher reintervention rates in both univariate and multivariate analyses.
目的
本文的主要目的是评估使用Endurant II(美敦力公司)和Zenith Flex(库克公司)血管内移植物对腹主动脉髂动脉瘤(AAA)进行血管内修复(EVAR)的患者,在与动脉瘤并发症相关的内漏、再次干预和死亡方面的结果。
方法
这是一项对接受使用Endurant II覆膜支架和Zenith Flex血管内移植物进行EVAR的AAA患者的前瞻性连续队列研究。
结果
共有156例接受EVAR的患者接受了评估。围手术期死亡率为5.1%,即8例患者。临床随访期的中位数为760±80天。有28例患者(17.9%)接受了动脉瘤的紧急修复(有症状的扩张或破裂),128例患者(82.1%)接受了择期修复。有36例(23.1%)出现了后期内漏,其中大多数为II型内漏(21例患者,13.4%)。有12例I型内漏。此外,关于肢体移植物闭塞(LGO),有9例患者(5.8%)。在整个队列中,Kaplan-Meier分析在720天时的总生存率为84.8%。在整个队列中,Kaplan-Meier分析在720天时的无再次干预率为92.7%。生存率的线性回归分析表明,慢性肾脏病(P = 0.03;风险比(HR)= 2.82,可信区间(CI)= 1.07 - 4.44)在单因素和多因素分析中都是与较差生存率相关的唯一因素。线性回归分析表明,内漏的存在(P < 0.001,HR = 6.69,CI = 2.26 - 8.48)和肢体移植物闭塞(P < 0.001,HR = 8.02,CI = 1.60 - 9.99)在单因素和多因素分析中都与再次干预相关。
结论
在本研究中,肾上固定血管内移植物装置在治疗AAA方面是安全有效的,结果令人满意且无肾脏损害。线性回归分析表明,内漏和肢体移植物闭塞的存在在单因素和多因素分析中都与较高的再次干预率相关。